Patient
P2B-086
completed Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · State Health Centre Oncology Department (Budapest, Hungary) (Dr. Clarke)
consented 2013-03-12
Adverse events
7
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 1 fatigue with onset in cycle 2 (2013-04-30); assessed as not related to study drug (unlikely); resolved 2013-05-24.
Grade 3 asthenia with onset in cycle 2 (2013-04-25); assessed as not related to study drug (unlikely); resolved 2013-05-09.
Grade 3 febrile neutropenia with onset in cycle 2 (2013-04-17); assessed as related to study drug (probable); resolved 2013-04-21.
Grade 3 neutropenia with onset in cycle 1 (2013-04-01); assessed as related to study drug (probable); resolved 2013-04-11; action: drug interrupted.
Grade 1 stomatitis with onset in cycle 1 (2013-03-27); assessed as related to study drug (probable); resolved 2013-04-04.
Grade 1 nausea with onset in cycle 1 (2013-03-25); assessed as not related to study drug (unlikely); resolved 2013-03-29.
Grade 2 vomiting with onset in cycle 1 (2013-03-25); assessed as not related to study drug (unlikely); resolved 2013-03-28.
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.